You are here

Compositions and methods for cancer expressing pde3a or slfn12

Application No.

PCT/US2016/046912

Broad Case No.

BI-2015/018

List of inventors -

Heidi Greulich, Matthew Meyerson, Luc De Waal, Monica Schenone, Xiaoyun Wu, Alex Burgin, Ulrike Sack

Abstract

The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).

Date PUBLISHED

  • 02/16/2017

PDF Download